From GlobeNewswire:

G1 Therapeutics, Inc. announced initial data from a Phase 2 trial combining trilaciclib with an antibody-drug conjugate (ADC) that shows a potentially meaningful improvement in overall survival for patients with triple negative breast cancer. The company also reported strong volume growth for COSELA in the fourth quarter of 2023 and expects an interim overall survival analysis of the pivotal 1L TNBC study in the first quarter of 2024. The company’s cash runway is expected to extend into 2025, and COSELA has seen high levels of satisfaction from prescribing oncologists and nurse practitioners/physician assistants. The company is focused on pursuing global opportunities for TNBC treatment through partnerships.



Read more: G1 Therapeutics Provides Corporate Update at the 42nd